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Abstract: A previously unreported bis-indolyl benzenoid, candidusin D (2e) and a new hydroxypyrrolidine
alkaloid, preussin C (5b) were isolated together with fourteen previously described compounds: palmitic
acid, clionasterol, ergosterol 5,8-endoperoxides, chrysophanic acid (1a), emodin (1b), six bis-indolyl
benzenoids including asterriquinol D dimethyl ether (2a), petromurin C (2b), kumbicin B (2c), kumbicin
A (2d), 2”-oxoasterriquinol D methyl ether (3), kumbicin D (4), the hydroxypyrrolidine alkaloid
preussin (5a), (3S, 6S)-3,6-dibenzylpiperazine-2,5-dione (6) and 4-(acetylamino) benzoic acid (7), from
the cultures of the marine sponge-associated fungus Aspergillus candidus KUFA 0062. Compounds
1a, 2a–e, 3, 4, 5a–b, and 6 were tested for their antibacterial activity against Gram-positive and
Gram-negative reference and multidrug-resistant strains isolated from the environment. Only 5a
exhibited an inhibitory effect against S. aureus ATCC 29213 and E. faecalis ATCC29212 as well as
both methicillin-resistant S. aureus (MRSA) and vancomycin-resistant enterococci (VRE) strains. Both
1a and 5a also reduced significant biofilm formation in E. coli ATCC 25922. Moreover, 2b and 5a
revealed a synergistic effect with oxacillin against MRSA S. aureus 66/1 while 5a exhibited a strong
synergistic effect with the antibiotic colistin against E. coli 1410/1. Compound 1a, 2a–e, 3, 4, 5a–b,
and 6 were also tested, together with the crude extract, for cytotoxic effect against eight cancer cell
lines: HepG2, HT29, HCT116, A549, A 375, MCF-7, U-251, and T98G. Except for 1a, 2a, 2d, 4, and 6,
all the compounds showed cytotoxicity against all the cancer cell lines tested.
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1. Introduction
Aspergillus candidus (Family Aspergillaceae) is a member of Aspergillus section Candidi [1].
This species frequently contaminates stored food and feeding stuff [2], and is one of the most
frequently encountered mold in cereal grains and flour [3]. It also occurs in soil, usually on seeds
or in the rhizosphere, and also in milk [4]. Strains of A. candidus produce a variety of secondary
metabolites including chlorflavonin, a chlorine containing flavone antifungal antibiotic [5], p-terphenyl
derivatives such as terphenyllin [6], deoxyterphenyllin [7], 3-hydroxyterphenyllin [8], candidusins
A and B [9], immunosuppressant terprenins [10]. On the other hand, there are only a few reports
on the chemical investigation of marine-derived A. candidus. Wei et al. [11] reported the isolation of
cytotoxic prenylterphyllin, 4”-deoxyprenylterphyllin, 4”-deoxyisoterprenin and 4”-deoxyterprenin
from A. candidus IF10, isolated from marine sediment. Recently, Wang et al. [12] described the isolation
of spiculisporic acid derivatives including the new compounds, spiculisporic acids F and G.
In our pursuit for antibiotic and anticancer compounds from marine-derived fungi from
the tropical sea, we have investigated secondary metabolites from cultures of A. candidus KUFA
0062, which were isolated from the marine sponge Epipolasis sp., collected from the coral reef at
the Similan Island National Park in Phang-Nga province, Southern Thailand.
Chromatographic fractionation and further purification of the crude ethyl acetate extract of
the cultures of A. candidus KUFA 0062, furnished two previously undescribed compounds named
candidusin D (2e) and preussin C (5b), as well as the previously reported chrysophanic acid
(1a) [13], emodin (1b) [14], six bis-indolyl benzenoids including asterriquinol D dimethyl ether
(2a) [15], petromurin C (2b) [16], kumbicin B (2c) [15], kumbicin A (2d) [15], 2”-oxoasterriquinol
D methyl ether (3) [17], kumbicin D (4) [15], the hydroxypyrrolidine alkaloid preussin (5a) [18–20],
(3S, 6S)-3,6-dibenzylpiperazine-2,5-dione (6) [21], and 4-(acetylamino) benzoic acid (7) [22] (Figure 1).
Additionally, the common fungal metabolites, i.e., palmitic acid, clionasterol [23], and ergosterol
5,8-endoperoxides [14] were also isolated (Supplementary Material, Figure S1).
Compounds 1a, 2a–e, 3, 4, 5a–b, and 6 were tested for their antibacterial activity against four
reference bacterial strains consisting of two Gram-positive (Staphylococcus aureus ATCC 29213 and
Enterococcus faecalis ATCC 29212) and two Gram-negative bacteria (Escherichia coli ATCC 25922
and Pseudomonas aeruginosa ATCC 27853), three multidrug-resistant isolates from the environment,
MRSA S. aureus 66/1, VRE E. faecalis B3/101, a colistin-resistant E. coli 1418/1, and a clinical
isolate ESBL E. coli SA/2. The isolated compounds were also investigated for their capacity to
inhibit biofilm formation in the four reference strains as well as for their potential synergism with
the clinically used antibiotics against multidrug-resistant isolates from the environment. Moreover,
these compounds were also evaluated for their cytotoxic effect against eight cancer cell lines, i.e., Hep
G2 (human hepatocellular carcinoma), HT29 (human colorectal adenocarcinoma), HCT116 (human
colorectal carcinoma), A549 (human lung carcinoma), A375 (human malignant melanoma), MCF7
(human mammary gland adenocarcinoma), U251 (human glioblastoma multiforme), and T98G (human
glioblastoma astrocytoma), by MTT assay.
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Figure 1. Structures of some secondary metabolites isolated from the cultures of the marine
sponge-associated fungus A. candidus KUFA 0062.
2. Results and Discussion
The structures of palmitic acid, clionasterol [22], ergosterol 5,8-endoperoxides [14], chrysophanic
acid (1a) [13], emodin (1b) [14], asterriquinol D dimethyl ether (2a) [15], petromurin C (2b) [16],
kumbicin B (2c) [15], kumbicin A (2d) [15], 2”-oxoasterriquinol D methyl ether (3) [17], kumbicin D
(4) [15], preussin (5a) [18–20], (3S, 6S)-3,6-dibenzylpiperazine-2,5-dione (6) [21] and 4-(acetylamino)
benzoic acid (7) [22] were elucidated by analysis of their 1D and 2D NMR spectra as well as HRMS
data, and also by comparison of their spectral data to those reported in the literature (Supplementary
Materials, Figures S2–S17, S20–S25, S32–S35 and Tables S1–S4).
Compound 2e was isolated as a white solid (m.p. 299–300 ◦C), and its molecular
formula C28H28N2O6 was established based on its (+)-HRESIMS m/z 489.2030 [M + H]+, (calculated
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489.2026 for C28H29N2O6), indicating sixteen degrees of unsaturation. The IR spectrum showed
absorption bands for amine (3346 cm−1), aromatic (1625, 1579 cm−1), and ether (1291 cm−1) groups.
The general features of the 1H and 13C NMR spectra of 2e (Table 1, Supplementary Materials,
Figures S18 and S19) resembled those of kumbicin A (2d), petromurin D (2b), and two bis-indolyl
benzenoids isolated from the soil fungus Aspergillus kumbius [15]. The 13C NMR spectrum (Table 1)
exhibited twelve carbon signals which, in combination with DEPTs and HSQC spectra, can be
categorized in six quaternary sp2 (δC 153.1, 147.6, 131.0, 127.4, 122.0, 106.7), four methine sp2 (δC 126.0,
111.9, 110.9, 102.1), and two methoxyl (δC 60.3, 55.3) carbon signals. As the number of the carbon
signals is less than the number of carbon atoms found in HRMS, the molecule must be symmetrical.
The presence of the 3,5-disubstituted indole moiety with the methoxyl group on C-5 was supported by
the presence of an amine proton at δH 11.15 (d, J = 2.2 Hz), a doublet at δH 7.43 (J = 2.5 Hz, H-2; δC
126.0), and the proton signals of the 1,2,3 substituted benzene ring at δH 6.78, dd (J = 8.8, 2.5 Hz, H-6;
δC 110.9), 6.88, d (J = 2.5 Hz, H-4; δC 102.1), 7.33, dd (J = 8.8, H-7; δC 111.9) as well as a singlet of OMe
at δH 3.72 (δC 55.3). That another portion of the molecule was 2,3,5,6-tetramethoxy-1,6-disubstituted
benzene ring was supported by the presence of the carbon signals at δH 122.0 (C-1 and C-6) and δC
147.6 (C-2, C-3, C-5, C-6) as well as four chemically and magnetically equivalent methoxyl groups at
δH 3.46 (δC 60.3). Putting together the HRMS and NMR data, the structure of 2e was established as
5′-methoxykumbicin B. However, instead of having one methoxyl group and one hydroxyl group on
C-5′ and C-5” of the indole ring system like petromurin D, the substituents on both C-5′ and C-5” are
methoxyl groups in 2e. To the best of our knowledge, 2e is a new analogue of bis-indolyl benzenoids,
which was named candidusin D.
Table 1. 1H and 13C NMR (DMSO, 300.13 and 75.4 MHz) and HMBC assignment for 2e.
Position δC, Type δH, (J in Hz)
1, 2, 4, 5 147.6, C -
3, 6 120.0, C -
NH-1′, 1” - 11.15, d (2.2)
2′, 2” 126.0, CH 7.43, d (2.5)
3′, 3” 106.7, C -
4′, 4” 102.1, CH 6.88, d (2.5)
5′, 5” 153.1, C -
6′, 6” 110.9, CH 6.78, dd (8.8, 2.5)
7′, 7” 111.9, CH 7.33, d (8.8)
8′, 8” 131.0, C -
9′, 9” 127.7 -
OCH3-1, 2, 4, 5 60.3, CH3 3.46, s
OCH3-5, 5′ 55.3, CH2 3.72, s
Compound 3 was isolated as white crystals (m.p. 290–292 ◦C) with [α]25D − 115.4 (c 0.04, MeOH).
Analysis of the (+)-HRESIMS, 1H, 13C NMR, COSY, HSQC, HMBC data of 3 (Table S3, Supplementary
Materials, Figures S20 and S21), revealed that this compound has the same planar structure as that
2”-oxoasterriquinol D methyl ether, an oxidized bis-indolyl benzenoid previously isolated from extracts
of the sclerotia of Aspergillus sclerotiorum (NRRL 5167) [17]. Although Whyte et al. [17] have found
that 2”-oxoasterriquinol D methyl ether was optically active, with [α]25D − 13.9 (c 0.001 g/mL, MeOH),
they did not determine the absolute configuration of the stereogenic carbon (C-3”) of the oxidized
indole ring system of this compound. In order to fully elucidate the structure of 3, we have attempted
to obtain suitable crystal for X-ray analysis. The results obtained, as seen in the ORTEP (Oak Ridge
Thermal-Ellipsoid Plot Program) view in Figure 2, revealed that although 3 was levorotatory, it was
not optically pure since both enantiomers were present in the crystal.
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Figure 2. ORTEP (Oak Ridge Thermal-Ellipsoid Plot Program) view of 3.
The (+)-HRESIMS, 1H, 13C NMR (Table 2), COSY, HSQC, and HMBC (Supplementary Materials,
Figures S24 and S25) data of 5a revealed that its planar structure is equal to that of the antifungal
compound L-657, 398, first isolated from the fermentation of Aspergillus ochraceus ATCC 22947 [18].
However, the authors failed to establish the relative stereochemistry of this compound by 1H NMR
data. The same compound, called preussin, was later isolated as a yellow oil ([α]25D + 22.0, c 1.0, CHCl3),
from the mycelial cake obtained from fermentation of a fungus Preussia sp. [19]. By comparison of
the chemical shift values of H2-1 and H2-6 of the (S)-and (R)-O-methylmandelate esters with those of
the acetate derivative of preussin, Johnson et al. [19] determined the absolute configurations of C-2,
C-3, and C-5 of preussin as 2S, 3S, and 5R.
Since we were able to obtain 5a as a suitable crystal, X-ray analysis was carried out to determine if
the absolute configurations of its stereogenic carbons were the same as those of preussin. The ORTEP
view of a protonated 5a, shown in Figure 3, not only determined the number of carbon atoms in
the alkyl side chain, but also confirmed the absolute configurations of C-2, C-3, and C-5 as 2S, 3S, and
5R. To the best of our knowledge, this is the first X-ray crystal structure of preussin.
Figure 3. ORTEP view of a protonated 5a.
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Compound 5b was isolated as a white crystal (m.p. 219–220 ◦C), and its molecular formula was
established as C20H33NO on the basis of its (+)-HRESIMS m/z 304.2647 [M + H]+, (calculated 304.2640
for C20H34NO), which indicated five degrees of unsaturation. The IR spectrum showed absorption
bands for hydroxyl and amine (3441 cm−1) and aromatic (1634, 1581, 1539 cm−1). The general features
of the 1H and 13C NMR spectra of 5b resembled those of 5a (Table 2, Supplementary Materials,
Figures S26, S27 and S29), except for the absence of the N-methyl singlet at δH 2.81 (δC 36.7), which was
confirmed by its molecular formula. Moreover, H2-1, H-3, H-4, and H2-6 appeared at lower frequencies
while H-2 and H-5 resonated at higher frequencies when compared to the corresponding protons in
5a. Additionally, the chemical shift values of C-2 and C-5 in 5b are around 10 ppm lower than those
of the corresponding carbons in 5a, while C-6 in 5b is around 3 ppm higher than that of C-6 in 5a.
Therefore, 5b is a N-demethyl analog of 5a. This hypothesis was confirmed by COSY correlations from
H-2 (δH 3.46, m; δC 65.2) to H-1a (δH 3.11, dd, J = 13.8, 8.0 Hz; δC 31.3), H-1b (δH 2.94, dd, J = 13.8, 6.6
Hz; δC 31.3) and H-3 (δH 4.09, dd, J = 7.9, 4.0 Hz; δC 68.7); H-3 to H-2, H-4β (δH 2.37, ddd, J = 13.9, 9.9,
5.5 Hz; δC 38.5) and OH-3 (δH 6.62, d, J = 4.0 Hz); H-5 (δH 4.09, dd, J = 7.9, 4.0 Hz; δC 68.7) to H-4β,
H-4α (δH 1.58, dd, J = 13.9, 5.8 Hz; δC 38.5) and H2-6 (δH 1.73, m/1.64, m; δC 33.6) as well as from
the methyl triplet at δH 0.86, t, (J = 6.8 Hz) to a brs at δH 1.26 (Table 2 and Supplementary Materials,
Figures S28 and 29). This was supported by HMBC correlations from H-1a and H-1b to C-2 and C-3;
H-2 to C-1; H-3 to C-2, C-5; OH-3 to C-2, C-3, C-4; H-4 to C-3, C-5 and C-6, and from H2-6 to C-4, C-5,
C-7 (Table 2 and Supplementary Materials, Figure S30). The relative stereochemistry of the pyrrolidine
ring of 5b was established, based on NOESY experiments, to be the same as that of 5a. The NOESY
spectrum (Table 2, Supplementary Materials, Figure S31) exhibited correlations from OH-3 to H-1a,
H-3 and H-4α; H-3 to H-2, OH-3 and H-4β; H-4β to H-3, H-4α and H-5, and from H-6 at δH 1.73, m to
H-4α. Since 5a can be hypothesized to derive from 5b through N-methylation by SAM, it is legitimate
to presume that the absolute configurations of C-2, C-3, and C-5 in 5b should be the same as those of
5a, i.e., 2S, 3S, 5R.
Since 5b could not be obtained as a suitable crystal for X-ray analysis, we have performed
a calculated Electronic Circular Dichroism (ECD) spectrum to compare with its experimental
ECD spectrum to determine unequivocally the absolute configurations of its C-2, C-3, and C-5.
Experimental NOESY data of 5b, as well as the data obtained from X-ray crystallographic and Trost’s
O-methylmandelate method [19] of 5a, suggest that all the pyrrolidine substituents of 5b are directed
to the same side of the ring. This formally narrows the investigation of the stereochemistry of 5b
to the enantiomer pair (2S, 3S, 5R) and (2R, 3R, 5S), combined with the two possible configurations
of the secondary amine. However, comparison of ECD simulated spectra for the above-mentioned
configurations of 5b, in its neutral forms, with the experimental spectrum in methanol was inconsistent
with the crystallographic configuration previously determined for its N-CH3 analogue (5a). Since
this analogue, most probably a metabolic derivative of 5b and therefore sharing the same (2S, 3S, 5R)
configuration, precipitated and crystalized as an ammonium salt, the same was assumed for 5b and
ECD simulations were therefore redirected to its protonated (positively charged) form.
This was expected to be a major difference since the calculated SCF HOMO and LUMO
orbitals show that the electronic transitions happen between the two rings. The new charge in
the five-membered ring alters significantly the electron density distribution and the molecular orbitals
energies. The electronic transitions associated with the hydrocarbon side-chain, however, do not
involve the five-membered ring and should remain unaffected. Additionally, these transitions are
predicted to be caused by wavelengths below 200 nm, hence outside the observational window.
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Table 2. 1H and 13C NMR of 5a (DMSO, 300.13 and 75.4 MHz) and 5b (DMSO, 300.13 and 75.4 MHz) and HMBC and NOESY assignments for 5b.
5a (DMSO, 300.13 and 75.4 MHz) 5b (DMSO, 500.13 and 125.4 MHz)
Position δC, Type δH, (J in Hz) δC, Type δH, (J in Hz) COSY HMBC NOESY
1a 30.6, CH2
3.69, dd (13.0, 9.4) 31.3, CH2
3.11, dd (13.8, 8.0) H-1b, 2 C-2, 3 H-1b, 2′, 6′
b 3.13, dd (12.7, 4.8) 2.94, dd (13.8, 6.6) H-1a, 2 C-2, 3 H-1a
2 76.0, CH 3.09, q (4.7) 65.5, CH 3.46, m H-1b, 1b, 3 C-1 H-3
3 68.6, CH 4.22, m 68.7, CH 4.09, dd (7.9, 4.0) H-2, 4β, OH-3 C-2, 5 H-2, H-4β, OH-3
4α 38.8, CH2
2.06, ddd (14.8, 9.3,
2.1) 38.5, CH2
1.58, dd (13.9, 5.8) H-3, 5 C-3, 5, 6 H-3, 4β, 5
β
2.69, ddd (15.0, 8.2,
8.2)
2.37, ddd (13.9, 9.9,
5.5) H-5 C-2, 3, 5, 6 H-4α, H-3
5 69.3, CH 2.92,m 57.6, CH 3.41, m H-4β, 4α, 6 C-4, 6, 7
6 30.1, CH2
2.25, m 33.6, CH2
1.73, m H-5 C-4, 5, 7
H-4α1.95, m 1.64, m H-5 C-4, 5, 7
7 26.5, CH2 1.40, m 26.1, CH2 1.26, brs
8 26.5, CH2 1.22, brs 28.6, CH2 1.26, brs
9 29.4, CH2 1.22, brs 28.9, CH2 1.26, brs
10 29.2, CH2 1.22, brs 28.8, CH2 1.26, brs
11 29.2, CH2 1.22, brs 28.7, CH2 1.26, brs
12 29.4, CH2 1.22, brs 31.6, CH2 1.26, brs
13 22.7, CH2 1.22, brs 22.1, CH2 1.26, brs
14 14.1, CH3 0.88, t (6.5) 14.0, CH3 0.86, t (6.8) H-13 C-12, 13
1′ 136.1, C - 137.4, C -
2′ 129.4, CH 7.31, m 129.1, CH 7.31, m C-1 H-1a, 1b, H2
3′ 128.9, CH 7.35, m 128.5, CH 7.34, m C-1
4′ 127.2, CH 7.25, m 126.6, CH 7.26, m C-2′, 6′
5′ 128.9, CH 7.31, m 128.5, CH 7.34, m C-1
6′ 129.4, CH 7.35, m 129.1, CH 7.31, m C-1 H-1a, 1b, H2
N-CH3 36.7, CH3 2.81, s - -
OH-3 - 5.12, d (11.7) - 5.62, d (4.0) H-3 C-2, 3, 4 H-1a, 3, 4β
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Models were constructed based only on the protonated (2S, 3S, 5R) configuration because
deprotonation upon dissolution of the secondary ammonium group is expected to be negligible.
The typically large pKa values (≈10) associated with these very weak acid groups in water is maintained
in methanol [24]. To have a good representation of 5b’s conformational space, the three staggered
orientations of C-1 (relative to C-2) and of 3-OH (relative to C-3) were combined with two five-membered
ring conformations to give 18 models. One, the lowest MM2 energy, staggered conformation of C-6
was set in all models, as well as a staggered linear conformation for the carbon chain. The orientation
of the phenyl group was always determined as a result of energy minimization. To have a notion of
its energetic ranking, the conformational energy of each of the 18 models was first minimized using
the semi-empirical PM6 method. Since the six lowest PM6-energy conformations accounted for 98% of
the conformer population, as determined by a Boltzmann distribution of computed PM6 conformational
energies, these were further minimized with the Amplitude Probability Density Function (APFD) Density
Functional Theory (DFT) method. The four lowest-energy APFD conformers were selected for ECD
simulation, also by the Boltzmann distribution significance. Figure 4 shows the lowest energy model.
The ECD transitions of the four models were calculated to a minimum wavelength of 170 nm with
the TDDFT method at the same level of theory than the final minimizations (APFD, with the same
basis set and solvent model). The four sets of transitions were Boltzmann weighed using the calculated
populations, Gaussian broadened by 0.17 eV and added to give the averaged simulated spectrum in
Figure 5. As is apparent, the fit with the experimental spectrum is good, representing well its three main
negative intensities (roughly at 215, 225 and 255 nm). This evidence supports the claim that the isolated
5b is the (2S, 3S, 5R) enantiomer (Figure 4) in the ammonium form.
Figure 4. The minimal APDF (Amplitude Probability Density Function) DFT (Density Functional
Theory) energy molecular model of amino-protonated 5b, in its (2S, 3S, 5R) configuration. The other
17 models tested differ in the conformation of the ring and in the orientations of the hydroxyl and
-CH2-C6H6 substituent groups.
Figure 5. Experimental (solid line) and simulated (dotted line) methanol ECD (Electronic Circular
Dichroism) spectra of 5b. The simulated spectrum of the (2S, 3S, 5R) model configuration fits well
the experimental data.
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Chrysophanic acid (1a), asterriquinol D dimethyl ether (2a), petromurin C (2b), kumbicin B (2c),
kumbicin A (2d), 2”-oxoesterriquinol D methyl ether (3), kumbicin D (4), preussin (5a), preussin C
(5b), and (3S, 6S)-3,6-dibenzylpiperazine-2,5-dione (6) were tested for their antibacterial activity and
their minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) for
four reference strains consisting of three multidrug-resistant isolates from the environment and one
clinical isolate. In the range of concentrations tested, none of the compounds were active against
Gram-negative bacteria. However, 5a displayed an inhibitory effect against Gram-positive bacteria,
with MIC values of 32 µg/mL for S. aureus ATCC 29213 and E. faecalis ATCC 29212. Moreover,
5a consistently showed a MIC value of 32 µg/mL for both methicillin-resistant S. aureus (MRSA) and
vancomycin-resistant enterococci (VRE) strains. Compound 5a also displayed a MBC value of 64
µg/mL for the VRE E. faecalis B3/101 strain, however, it was not possible to determine the MBC for
the other Gram-positive strains. This result suggests that 5a might not only have a bacteriostatic effect
but also a bactericidal action.
The effect of 1a, 2a–e, 3, 4, 5a, b, and 6 on biofilm formation in four reference bacterial strains
was also evaluated. Four concentrations of 5a, ranging from 2 ×MIC to 14 MIC were tested against S.
aureus ATCC 2913 and E. faecalis ATCC 2912. Since it was not possible to determine a MIC of the rest of
the other compounds, the previously tested highest concentration that did not inhibit bacterial growth
was used. Although none of the compounds tested showed an inhibitory effect on biomass production
in P. aeruginosa ATCC 27853, the anthraquinone chrysophanic acid (1a) induced significant reduction
in biofilm formation (67.7 ± 8.3% of control; One-sample t test: * p < 0.05, significantly different from
100%) in E. coli ATCC 25922. Interestingly, 5a also caused an almost 50% reduction of biofilm mass
production (42.8 ± 32.7% of control) at a sub-inhibitory concentration in E. coli ATCC 25922. Although
this inhibitory effect was not statistically significant, this result shows an interesting aspect in that 5a is
active against both Gram-positive and Gram-negative bacteria. In fact, among the compounds tested,
only 5a was capable of interfering with biofilm formation in S. aureus ATCC 29213 and E. faecalis ATCC
29212 at concentrations equal to or above the MIC (Figure 6), however, at lower concentrations, 5a had
no effect on the biomass production of both strains.
Figure 6. Gram-positive bacteria biofilm biomass production after 24 h of incubation with different
concentrations of compound 5a. Data are shown as Mean ± SD of the three independent experiments.
One-sample t test: ** p < 0.01 and *** p < 0.001, significantly different from 100%. MIC, minimum
inhibitory concentration.
The tested compounds were also screened for their potential synergies with the clinically relevant
antibiotics and some of them revealed small to moderate synergistic associations with antibiotic as
determined by the disk diffusion method. Except 5a, which presented an inhibition zone of 8 mm
for VRE E. faecalis B3/101 and MRSA S. aureus 66/1, the rest of the tested compounds showed no
inhibition zone (0 mm), when tested alone. The combination of 2a–d, 3, 4, 5a, and 6 with cefotaxime
in impregnated disks resulted in a minor synergistic effect, as can be observed by a small increase
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in the zone of inhibition when compared with the halo of inhibition produced by cefotaxime alone
in an ESBL E. coli strain (SA/2). In the case of VRE E. faecalis B3/101, all the tested compounds
induced a small increase in the halo of a partial inhibition of vancomycin when compared with
vancomycin alone, however, this effect was more pronounced with 5a. On the other hand, only 2b
and 5a revealed a synergistic effect with oxacillin against MRSA S. aureus 66/1. Interestingly, although
2b alone did not exhibit the antibacterial effect, it showed a marked synergistic effect with oxacillin,
increasing the halo of inhibition from 0 mm, when oxacillin was used alone, to 7 mm when tested in
combination. These results were also confirmed by the checkerboard method since the combination of
5a with vancomycin and oxacillin showed the values of ΣFIC ≤ 0.5 against VRE and MRSA isolates,
respectively (Table 3).
Table 3. Fractional inhibitory concentration (FIC) index of 5a in combination with clinically relevant
antibiotics obtained by the checkerboard method.
Bacterial Strain
5a-Van 5a-Ox
ΣFIC Activity ΣFIC Activity
E. faecalis B3/101 (VRE) 0.4 S - -
S. aureus 66/1 (MRSA) - - 0.2 S
S = synergism; VAN = vancomycin; OX = oxacillin.
Interestingly, 5a also demonstrated a strong synergistic effect with colistin, reducing MIC of
colistin from 8 µg/mL to less than 0.008 µg/mL, i.e., at least 100-fold, when tested against E. coli
1410/1 (Table 4). Following this result, lower concentrations of 5a were tested and it was found
that a concentration of 8 µg/mL of 5a was enough to alter E. coli 1410/1 resistance to colistin, thus
decreasing colistin MIC to 1 µg/mL (susceptibility breakpoint of ≤0.2 µg/mL) [25].
Table 4. Combined effect of colistin with 5a against colistin resistant E. coli strain 1410/1. MICs for
colistin are expressed in µg/mL.
Compound µg/mL of 5a + Colistin
5a 0 1 2 4 8 16 32 64
Colistin (MIC) 8 R 8 R 8 R 4 R 1 S 0.016 S <0.008 S <0.008 S
MIC = minimum inhibitory concentration; R = resistant; S = sensitive.
With the exception of 2b, the modest synergistic effects observed by the disk diffusion method
were not replicated when the MIC of the antibiotics was determined in the presence of the tested
compounds. The MIC of oxacillin, in a combination with 2b, was four folds less than that of oxacillin
alone (from 64 µg/mL to 16 µg/mL) when tested against MRSA S. aureus 66/1. Although no effect
on MIC of the antibiotics was observed with any other compounds, it is likely that since the method
used for determination of the MIC requires two-fold serial dilutions, the synergistic effect between
the antibiotics and the test compounds might not be enough to decrease the MIC of the antibiotics by
a factor of two, in case the absolute difference between the two consecutive concentrations is large.
This reasoning can justify the difference in the results obtained using two different methods.
The cytotoxic effect of the ethyl acetate crude extract of A. candidus KUFA 0062 (200 µg/mL) and
1a, 2a–e, 3, 4, 5a, b, and 6, at only one concentration (100 µM), were tested against eight cancer cell
lines, i.e., Hep G2, HT29, HCT116, A549, A375, MCF7, U251, and T98G by MTT assay. At 200 µg/mL,
the crude extract significantly decreased cell viability in all cell lines tested, with higher cytotoxic
effect in A375 > HT29 > HCT116 > HepG2 > A549 > T98G > MCF7 > U251 cells. At 100 µM, 5a was
found to decrease the cell viability in all cell lines tested, reaching the lowest % of cell viability in colon
cancer cell lines (6.4% and 8.6% in HCT116 and HT29, respectively). Compound 5b also decreased cell
viability in all of the cell lines tested, however, it was less effective than 5a. Except for human malignant
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glioma U251 and T98G cells, 2b significantly decreased the number of viable cells in all the cell lines
tested (with cell viability less than 50). Similarly, 2e and 3 also exhibited a significant decrease of cell
viability in all cell lines tested except for T98G and HepG2 for 2e and HepG2 for 3. Compound 2c
significantly decreased cell viability in the HepG2, HT29, HCT116, A549, and A375 cells. Compounds
1a, 2a, 2d, 4 and 6, at 100 µM, did not change cell viability in any of the cancer cell lines tested (Table 5).
In view of these results, dose-response curves were constructed to determine IC50 values only for
compounds and cell lines whose significant cytotoxic effects were observed. Doxorubicin (Dox) was
used as a positive control. The IC50 values and respective 95% confidence intervals are summarized in
Table 6. Compound 5a was the most effective in all the cell lines tested with IC50 ranging from 12.3 µM
in HT29 cells to 74.1 µM in U251 cells while 2b also induced a significant decrease of cell viability
with IC50 values ranging from 34.8 µM in H29 cells to 94.8 µM in MCF7 cells. On the other hand,
3 was more cytotoxic in HT29 cells with IC50 value of 43.2 µM but less cytotoxic in U251 cells with
IC50 value of 120.2 µM. Compound 5b showed IC50 values ranging from 57.2 µM (in HT29 cells) to
215.7 µM (in A549 cells). Compound 2c and 2e significantly decreased cell viability but with higher
IC50 values ranging from 72.9 µM (2c in HCT116 cells) to 186.6 µM (2e in MCF7 cells). Over all, it can
be observed that while 2b, 3, 5a, and 5b were more effective in HT29 cells, 2c and 2e were more active
in HCT116 cells. This suggests that these compounds may act by different mechanisms of action since
each cell line has different genetic characteristics. As to the positive control, Dox, we have observed
a decrease in cell viability in all cell lines with IC50 values ranging from 0.05 µM (in A375 cells) to
15.4 µM (in T98G cells). Our findings are in agreement with the literature showing that HT29 was
more resistant to the cytotoxic effect of Dox than the HCT116 cells [26].
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Table 5. Percentage of cell viability relative to control of 1a, 2a–e, 3, 4, 5a, b, 6 (100 µM) and crude extract of A. candidus KUFA 0062 (200 µg/mL) in eight human
cancer cell lines after 48 h of incubation as assessed by MTT assay.
The results are the mean (SD) of at least four independent experiments, each in duplicate. Significant differences (** p < 0.01; *** p < 0.001 and **** p<0.0001) when compared with
control cells were evaluated by one-way ANOVA, followed by the post-hoc Dunnett’s test. # Indicates significant differences when 5b is compared with 5a, as evaluated by a t-test.
Compounds/extract are marked in light gray when cell viability is equal to or greater than 50% and in dark gray when cell viability is lower than 50% relative to control. n.d.—not
determined.
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Table 6. IC50 values (half-maximal inhibitory concentration) and respective 95% confidence intervals of compounds tested in eight human cancer cell lines, determined
by the MTT assay.
IC50 (95% CI)
Compounds (µM) HepG2 HT29 HCT116 A549 A375 MCF7 U251 T98G
2b
56.3 34.8 60.8 84.1 82.8 94.8
n.d. n.d.(37.9–83.7) (22.0–55.0) (41.6–88.8) (60.3–117.1) (50.5–123.8) (63.2–142.3)
2c
123.8 113.7 72.9 109.0 146.4
n.d. n.d. n.d.(86.4–177.5) (78.9–163.8) (56.0–94.9) (66.2–179.5) (102.3–209.4)
2e
118.9 111.6 73.2 105.8 123.1 186.8 212.5
n.d.(88.9–159.0) (85.9–145.0) (59.3–90.4) (72.8–153.7) (91.9–164.9) (155.1–224.8) (156.2–289.2)
3 n.d.
43.2 64.1 85.2 109.8 99.7 120.2
n.d.(28.3–65.7) (42.9–95.7) (61.9–117.3) (76.4–157.6) (70.8–143.0) (81.2–177.7)
5a
43.2 12.3 29.8 47.9 38.5 53.6 74.1 50.4
(30.7–60.8) (10.1–15.5) (19.1–46.6) (33.2–69.0) (29.8–49.7) (39.4–72.9) (54–0–101.6) (32.0–79.4)
5b
153.4 57.2 124.8 215.7 148.5 128.8 128.6 –
(96.2–244.7) (41.7–78.4) (94.9–164.1) (161.4–288.1) (103.7–212.4) (94.5–175.5) (86.7–190.8)
Dox
0.12 0.63 0.29 0.24 0.05 0.36 1.11 15.4
(0.07–0.22) (0.26–1.12) (0.16–0.54) (0.13–0.08) (0.03–0.08) (0.16–0.84) (0.43–2.85) (10.4–22.9)
n.d.: IC50 not determined because no cytotoxicity was observed at 100 µM. IC50 values (in µM) are the mean of at least four independent experiments, each in duplicate. Doxorubicin (Dox)
was used.
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The results are the mean (SD) of at least four independent experiments, each in duplicate.
Significant differences (** p < 0.01; *** p < 0.001 and **** p < 0.0001) when compared with control cells
were evaluated by one-way ANOVA, followed by the post-hoc Dunnett’s test. # Indicates significant
differences when 5b is compared with 5a, as evaluated by a t-test. Compounds/extract are marked in
light gray when cell viability is equal to or greater than 50% and in dark gray when cell viability is
lower than 50% relative to control. n.d.—not determined.
3. Experimental Section
3.1. General Experimental Procedures
Melting points were determined on a Bock monoscope and are uncorrected. Optical rotations
were measured on an ADP410 Polarimeter (Bellingham + Stanley Ltd., Tunbridge Wells, Kent, UK).
Infrared spectra were recorded in a KBr microplate in a FTIR spectrometer Nicolet iS10 from Thermo
Scientific (Waltham, MA, USA) with Smart OMNI-Transmission accessory (Software 188 OMNIC 8.3).
1H and 13C NMR spectra were recorded at ambient temperature on a Bruker AMC instrument (Bruker
Biosciences Corporation, Billerica, MA, USA) operating at 300 or 500 and 75 or 125 MHz, respectively.
High resolution mass spectra were measured with a Waters Xevo QToF mass spectrometer (Waters
Corporations, Milford, MA, USA) coupled to a Waters Aquity UPLC system. A Merck (Darmstadt,
Germany) silica gel GF254 was used for preparative TLC, and a Merck Si gel 60 (0.2–0.5 mm) was used
for column chromatography.
3.2. Fungal Material
The strain KUFA 0062 was isolated from the marine sponge Epipolasis sp., which was collected, by
scuba diving at a depth of 15–20 m from the coral reef at Similan Island National Park (8◦39′09” N,
97◦38′27” E), Phang-Nga province, Southern Thailand, in April 2010. The sponge was washed with
0.06% sodium hypochlorite solution for 1 min, followed by sterilized seawater three times, and then
dried on sterile filter paper under a sterile aseptic condition. The sponge was cut into small pieces
(5 × 5 mm), and placed on Petri dish plates containing 15 mL malt extract agar (MEA) medium with
70% seawater and 300 mg/L of streptomycin sulfate and incubated at 28 ◦C for 7 days. The hyphal
tips emerging from the sponge pieces were individually transferred onto a MEA slant and maintained
as pure culture for further identification.
The fungus was identified as Aspergillus candidus, based on morphological characters as described
by Varga et al. [27].This identification was supported by molecular techniques using ITS primers.
DNA was extracted from young mycelia following a modified Murray and Thompson method [28].
Primer pairs ITS1 and ITS4 [29] were used for ITS gene amplification. PCR reactions were conducted
on Thermal Cycler and the amplification process consisted of initial denaturation at 95 ◦C for 5 min,
34 cycles at 95 ◦C for 1 min (denaturation), at 55 ◦C for 1 min (annealing) and at 72 ◦C for 1.5 min
(extension), followed by a final extension at 72 ◦C for 10 min. PCR products were examined by Agarose
gel electrophoresis (1% agarose with 1 × TBE buffer) and visualized under UV light after staining
with ethidium bromide. DNA sequencing analyses were sequenced using the dideoxyribonucleotide
chain termination method [30] by Macrogen Inc. (Seoul, Korea). The DNA sequences were edited
using FinchTV software and submitted into the BLAST program for alignment and compared with
that of fungal species in the NCBI database (http://www.ncbi.nlm.nih.gov/). Its gene sequences were
deposited in GenBank with accession numbers KX 431210. The pure cultures were deposited as KUFA
0062 at Kasetsart University Fungal Collection, Department of Plant Pathology, Faculty of Agriculture,
Kasetsart University, Bangkok, Thailand.
3.3. Extraction and Isolation
The fungus was cultured for one week at 28 ◦C in five Petri dishes (i.d. 90 mm) containing 15 mL
of potato dextrose agar per dish. In order to obtain the mycelial suspension, the mycelial plugs were
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transferred to two 500 mL Erlenmeyer flasks containing 250 mL of potato dextrose broth, and then
incubated on a rotary shaker at 150 rpm at 28 ◦C for 7 days. Fifty 1000 mL Erlenmeyer flasks, each
containing 200 g of cooked rice, were autoclaved at 121 ◦C for 15 min, and then inoculated with 25 mL
of mycelial suspension of A. candidus, and incubated at 28 ◦C for 30 days, after which the moldy
rice was macerated in ethyl acetate (25 L total) for 7 days, and then filtered with Whatman No. 1
filter paper. The ethyl acetate solutions were combined and concentrated under reduced pressure
to yield 53 g of crude ethyl acetate extract, which was dissolved in 1000 mL of CHCl3, and filtered
with Whatman No. 1 filter paper. The chloroform solution was then washed with H2O (3 × 500 mL)
and dried with anhydrous Na2SO4, filtered and evaporated under reduced pressure to give 50 g
of the crude chloroform extract, which was applied on a column of silica gel (420 g) and eluted
with mixtures of petrol-CHCl3 and CHCl3-Me2CO, wherein the 250 mL fractions were collected as
follow: Frs 1–80 (petrol-CHCl3, 1:1), 81–220 (petrol-CHCl3, 3:7), 221–350 (petrol-CHCl3, 1:9), 351–579
(CHCl3), 580–680 (CHCl3-Me2CO, 9.5:0.5), 681–730 (CHCl3-Me2CO, 9:1), 731–822 (CHCl3-Me2CO,
7:3). Frs 8–19 were combined (43.0 mg) and recrystallized in MeOH to give 17.4 mg of a yellow
solid, which was identified as chrysopharic acid (1a) [13]. Frs 79–90 were combined (879.2 mg)
and precipitated in MeOH to give 86.1 mg of clionasterol [23]. Frs. 91–118 were combined (2.49 g)
and precipitated in MeOH to give 1.0 mg of palmitic acid. Frs 462–517 were combined (253.9 mg)
and recrystallized in MeOH to give 31.4 mg of an orange solid of emodin (1b) [14]. Frs 528–583
were combined (535.8 mg) and precipitated in MeOH to give 254.4 mg of kumbicin D (4) [15], and
the mother liquor that was crystallized in MeOH to give 11.8 mg of β-ergosterol 5,8-endoperoxide [14].
Frs 586–588 were combined (1.16 g) and recrystallized in Me2CO to give 345.0 mg of white crystal
of asterriquinol D dimethyl ether (2a) [15]. Frs 589–591 were combined (780.0 mg) and precipitated
in Me2CO to give a white solid, which was crystallized in MeOH to give 52.7 mg of kumbicin B
(2c) [15], and the mother liquor was dried and recrystallized in Me2CO to give 21.6 mg of candidusin
D (2e). Frs 610–618 were combined (870.6 mg) and crystallized in a mixture of CHCl3 and MeOH to
give 250.6 mg of petromurin C (2b) [16]. The mother liquor of frs 610–618 (620.0 mg) was combined
with frs. 594–609 (2.46 g) and frs 619–652 (1.29 g), and applied on a column chromatography of
silica gel (130 g), and eluted with mixtures of petrol-CHCl3 and CHCl3-Me2CO, wherein 250 mL sfrs
were collected as follow: Sfrs 1–35 (petrol-CHCl3, 3:7), 36–60 (petrol-CHCl3, 1:9), 61–100 (CHCl3),
101–120 (CHCl3-Me2CO, 9:1), 121–127 (CHCl3-Me2CO, 7:3). Sfrs 81–84 were combined (55.8 mg) and
precipitated in Me2CO to give 16.3 mg of 2”-oxoasterriquinol D methyl ether (3) [17]. Sfrs 85–89 were
combined (102.3 mg) and precipitated in CHCl3 to give 30.0 mg of petromurin C (2b). Frs 680–770
were combined (5.81 g) and applied on a column chromatography of silica gel (130 g), and eluted
with mixtures of petrol-CHCl3, CHCl3-Me2CO, wherein 250 mL fractions were collected as follow:
Sfrs 1–30 (petrol-CHCl3, 3:7), 31–77 (petrol-CHCl3, 1:9), 78–101 (CHCl3), 102–145 (CHCl3-Me2CO, 9:1).
Sfrs 88–104 were combined (373.3 mg) and recrystallized in a mixture of CHCl3 and Me2CO to give
131.9 mg of preussin (5a) [18,19]. Frs 709–722 were combined (814.7 mg) and precipitated in MeOH to
give 8 mg of (3S, 6S)-3,6-dibenzylpiperazine-2,5-dione (6). Frs 757–764 were combined (1.20 g) and
precipitated in Me2CO to give 7 mg of kumbicin A (2d). Frs 789–791 were combined (1.01 g) and
applied over a column chromatography of Sephadex LH-20 (20 g) and eluted with MeOH, wherein 30
sfrs of 10 mL were collected. Sfrs 24–26 were combined (48.7 mg) and precipitated in Me2CO to give
7.1 mg of 4-acetylamino benzoic acid (7) [22]. Frs 792–806 were combined (559.4 mg) and applied over
a column chromatography of Sephadex LH-20 (20 g), and eluted with MeOH, wherein 40 sfrs of 10 mL
were collected. Sfrs 8–14 were combined (350.4 mg) and precipitated in Me2CO to 25 mg of preussin C
(5b). Frs 807–822 were combined (416.1 mg) and precipitated in a mixed CHCl3 and Me2CO to give an
additional 22.1 mg of preussin C (5b).
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3.3.1. Candidusin D (2e)
White solid, m.p. 299–300 ◦C (CHCl3/MeOH); IR (KBr) νmax 3346, 2990, 2935, 1625, 1579, 1484,
1459, 1390, 1291 cm−1; For 1H and 13C spectroscopic data (DMSO, 300.13 and 75.4 MHz), see Table 1;
(+)-HRESIMS m/z 489.2030 (M + H)+ (calculated for C28H29N2O6, 489.2026).
3.3.2. Preussin C (5b)
White solid, m.p. 219–220 ◦C (CHCl3/MeOH); [α]23D + 28.6 (c 0.04, MeOH); IR (KBr) νmax 3443,
2958, 2921, 2851, 2803, 2360, 2341,1651, 1634, 1581, 1470, 1411, 1261, 1095, 1031, 803 cm−1; For 1H and
13C spectroscopic data, see Table 2; (+)-HRESIMS m/z 304.2647 (M + H)+ (calculated for C20H34NO,
304.2640).
3.4. Electronic Circular Dichroism
Experimental ECD spectra were obtained with a Jasco J-815 CD spectropolarimeter in a 0.1 mm
cuvette. The model construction, dihedral driver search, and MM2 minimizations were done in
Chem3D Ultra (Perkin-Elmer Inc., Waltham, MA, USA). All other conformational energy minimization
and spectral calculations (TDDFT method) were performed with Gaussian 16W (Gaussian Inc.,
Wallingford, CT, USA) at the PM6 or APFD/6-311+G(2d,p) level [31] with the IEFPCM methanol
solvation model. The simulated spectral lines were obtained by summation of Gaussian curves, as
recommended in [32]. ECD spectra were added using Boltzmann weights derived from its minimal
APFD energies [33].
3.5. X-ray Crystal Structure of 3 and 5a
Single crystals were mounted on cryoloops using paratone. X-ray diffraction data were collected
at room temperature with a Gemini PX Ultra equipped with CuKα radiation (λ = 1.54184 Å).
The structures were solved by direct methods using SHELXS-97 and refined with SHELXL-97 [34].
Non-hydrogen atoms were refined anisotropically. Hydrogen atoms were either placed at their
idealized positions using appropriate HFIX instructions in SHELXL and included in subsequent
refinement cycles or were directly found from difference Fourier maps and were refined freely with
isotropic displacement parameters.
Full details of the data collection and refinement and tables of atomic coordinates, bond lengths
and angles, and torsion angles have been deposited with the Cambridge Crystallographic Data Centre.
2”-Oxoasterriquinol D methyl ether (3). Crystal was triclinic, space group P-1, cell volume
1212.4(3) Å3 and unit cell dimensions a = 9.364(2) Å, b = 11.3095(10) Å and c = 12.5789(12) Å and angles
α = 105.760(8)◦, β = 102.321(14)◦ and γ = 100.259(13)◦ (uncertainties in parentheses). There are two
molecules per unit cell with calculated density of 1.212 g/cm−3. Crystal has an inversion center (space
group P-1) and thus the two molecules in the unit cell are enantiomers. The refinement converged to R
(all data) = 15.23% and wR2 (all data) = 41.23%. (CCDC 1823071).
Preussin (5a). Crystal was triclinic, space group P1, cell volume 547.58(10) Å3 and unit cell
dimensions a = 5.8517(5) Å, b = 7.0327(6) Å and c = 14.2627(19) Å and angles α = 79.947(10)◦,
β = 79.515(9)◦ and γ = 73.094(7)◦ (uncertainties in parentheses). Calculated density of 1.073 g/cm−3.
The absolute structure was established with confidence (Flack parameter = 0.018(15)). The refinement
converged to R (all data) = 3.42% and wR2 (all data) = 8.07%. (CCDC 1823438).
3.6. Antibacterial Activity Bioassays
3.6.1. Bacterial Strains and Growth Conditions
Four reference and three multidrug-resistant bacterial strains were used in this study.
The Gram-positive bacteria comprised Staphylococcus aureus ATCC 29213, Enterococcus faecalis
ATCC 29212, MRSA S. aureus 66/1 isolated from public buses [35], and VRE E. faecalis B3/101
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isolated from river water [36]. The Gram-negative bacteria used were Escherichia coli ATCC 25922,
Pseudomonas aeruginosa ATCC 27853, a colistin-resistant E. coli 1418/1 strain isolated from rabbit feces,
and a clinical isolate ESBL E. coli SA/2. Frozen stocks of all strains were grown in Mueller-Hinton agar
(MH-BioKar diagnostics, Allone, France) at 37 ◦C. All bacterial strains were sub-cultured in MH agar
and incubated overnight at 37 ◦C before each assay.
3.6.2. Antimicrobial Susceptibility Testing
The minimum inhibitory concentration (MIC) was used for determining the antibacterial activity
of each compound, in accordance with the recommendations of the Clinical and Laboratory Standards
Institute (CLSI) [37]. With the exception of 6, 10 mg/mL stock solutions of each compound were
prepared in dimethylsulfoxide (DMSO—Applichem GmbH, Darmstadt, Germany). For 6, which was
less soluble in DMSO than the other compounds, a stock solution of 1 mg/mL was prepared. Two-fold
serial dilutions of the compounds were prepared in Mueller-Hinton broth 2 (MHB2—Sigma-Aldrich,
St. Louis, MO, USA) within the concentration range of 0.062–64 µg/mL, except for 6 for which
the highest concentration tested was 32 µg/mL. The highest concentration tested was chosen in
order to maintain DMSO in-test concentration below 1% as recommended by the CLSI [37]. At this
concentration DMSO did not affected bacterial growth. Cefotaxime (CTX) ranging between 0.031 and
16 µg/mL was used as a control. A purity check and colony counts of the inoculum suspensions were
also evaluated in order to ensure that the final inoculum density closely approximates the intended
number (5 × 105 CFU/mL). The MIC was determined as the lowest concentration at which no visible
growth was observed. The minimum bactericidal concentration (MBC) was assessed by spreading
10 µL of culture collected from wells showing no visible growth on MH agar plates. The MBC was
determined as the lowest concentration at which no colonies grew after 16–18 h incubation at 37 ◦C.
These assays were performed in duplicate.
3.6.3. Biofilm Formation Inhibition Assay
The effect of all compounds on biofilm formation was assessed using crystal violet staining as
previously described [38]. Briefly, the highest concentration tested in the MIC assay was added to
bacterial suspensions of 1 × 106 CFU/mL prepared in Tryptic Soy broth (TSB-BioKar diagnostics,
Allonne, France). When it was possible to determine a MIC, four concentrations were tested: 2 ×MIC,
MIC, 12 MIC, and
1
4 MIC. A control without any compound as well as a negative control (TSB
alone) were included. The stabilized biofilm mass was quantified after 24 h incubation at 37 ◦C.
The absorbance was measured at 595 nm on an iMark™ microplate spectrophotometer (Bio-Rad
Laboratories, Hercules, CA, USA). The background absorbance (TSB without inoculum) was subtracted
from the absorbance of each sample and data are shown as a percentage of control. Three independent
experiments were performed in triplicate for each experimental condition.
3.6.4. Antibiotic Synergy Testing
In order to evaluate the combined effect of the compounds and clinically relevant antimicrobial
drugs, a screening was conducted using the disk diffusion method, as previously described [38,39].
A set of antibiotic disks (Oxoid, Basingstoke, UK) to which the isolates were resistant was selected:
cefotaxime (CTX, 30 µg) for E. coli SA/2, oxacillin (OX, 1 µg) for S. aureus 66/1, and vancomycin (VA, 30
µg) for E. faecalis B3/101. Antibiotic disks alone (controls) and antibiotic disks impregnated with 15
µg of each compound were placed on MH agar plates seeded with the respective bacteria. Sterile 6
mm blank paper disks (Oxoid, Basingstoke, UK) impregnated with 15 µg of each compound alone
were also tested. A blank disk with DMSO was used as a negative control. MH inoculated plates were
incubated for 18–20 h at 37 ◦C. Potential synergism was recorded when the halo of an antibiotic disk
impregnated with a compound was greater than the halo of the antibiotic or compound-impregnated
blank disk alone.
Mar. Drugs 2018, 16, 119 18 of 22
The potential synergy between the most promising compounds and clinically relevant
antibiotics (oxacillin and vancomycin—Sigma-Aldrich, St. Louis, MO, USA) was also evaluated
by the checkerboard method as previously described [38]. For this purpose multidrug-resistant strains
were selected based on their resistance towards those antibiotics. The fractional concentration (FIC)
was calculated as follows: FIC of drug A (FIC A) = MIC of drug A in combination/MIC of drug A
alone, and FIC of drug B (FIC B) = MIC of drug B in combination/MIC of drug B alone. The FIC
index was calculated as the sum of each FIC and interpreted as follows: ΣFIC ≤ 0.5, synergy; 0.5 <
ΣFIC ≤ 4, no interaction; 4 < ΣFIC, antagonism [40]. When it was not possible to determine a MIC
value for the test compound, the potential synergy between the compounds and clinically relevant
antibiotics was evaluated by determining the antibiotic MIC in the presence of each compound.
Briefly, the MIC of CTX, OX, VA, and colistin (Sigma-Aldrich, St. Louis, MO, USA) for the respective
multidrug-resistant strains was determined in the presence of the highest concentration of each
compound tested, unless otherwise stated, that did not affect bacterial growth when the compound
was used alone. The antibiotic tested was serially diluted whereas the concentration of each compound
was kept fixed. In the case of 6 the concentration used was 32 µg/mL. For all other compounds
the concentration used was 64 µg/mL. Antibiotic MICs where determined as described above.
3.7. In Vitro Anticancer Activity Assays
3.7.1. Cell Lines
Eight cancer cell lines were used to assess the anticancer activity of the extract and isolated
compounds of the marine sponge-associated fungus Aspergillus candidus KUFA 0062. HT29, HCT116
cells were kindly provided by Prof. Carmen Jerónimo, from CI-IPO, Porto and HepG2 cells were
provided by Prof. Rosário Martins, from ESTSP and CIIMAR, Porto. A375, A549, MCF7, U-251 and
T98G cell lines were obtained from the European Collection of Cell Cultures. Cells were maintained
as monolayer cultures in DMEM supplemented with 10% FBS, 1% antibiotic solution (100 U/mL
penicillin and 100 µg/mL streptomycin), 10 mM N-[2-hydroxyethyl] piperazine-N′-[2-ethane-sulfonic
acid] and 0.1 mM sodium pyruvate in a humidified incubator with 5% CO2 at 37 ◦C. Cells were
trypsinized near the confluence. Stock solutions of the isolated compounds, extract and Dox were
prepared in dimethyl sulphoxide (DMSO) and aliquots and kept at −20 ◦C. For experiments, the final
concentration of DMSO in the medium was < 0.1% (v/v) and the controls received DMSO only.
3.7.2. MTT Reduction Assay
To assess the effects of the isolated compounds and the extract on cell viability, cells were plated in
96-multiwell culture plates at a density of 0.1 × 106 cells/mL. After cell adhesion, cells were incubated
for 48 h with fresh medium containing the isolated compounds, at 100 µM, and extract, at 200 µg/mL,
and cell viability was measured by MTT reduction assay as described previously [41]. Briefly, after
48 h of treatment MTT was added at a final concentration of 0.5 mg/mL and incubated for 2 h at 37 ◦C.
The formazan crystals were dissolved in a DMSO: EtOH solution (1:1) (v/v) and the absorbance was
measured at 570 nm in a microplate reader (Multiskan Ex, Labsystems, Milford, MA, USA).
The determination of IC50 (half-maximal inhibitory concentration) was performed only for
the isolated compounds that significantly decrease cell viability at 100 µM. For this, cancer cell lines
were incubated with different concentrations of isolated compounds (0–200 µM) or Dox (0.001–10 µM),
as a positive control, and the MTT assay was performed as described above. The IC50 values were
determined using GraphPad Prism v6.0 software (GraphPad Software, La Jolla, CA, USA). This software
was also used to conduct the statistical analysis, using a one-way ANOVA, followed by the post-hoc
Dunnett’s test. The normality and homogeneity of variance were confirmed by the Shapiro-Wilk test
and Levine test, respectively. The significance level was set at the conventional 95%.
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4. Conclusions
Most of the investigations of the secondary metabolites of the fungus Aspergillus candidus were
carried out with its terrestrial strains. Except for a chlorine containing flavone antifungal antibiotic
chlorflavonin, the secondary metabolites produced by this fungal species were p-terphenyl and
bis-indolyl benzenoids derivatives, some of which immunosuppressive activity, cytotoxicity against
sea urchin embryos and various tumor cell lines. Interestingly, to the best of our knowledge, only
two marine-derived A. candidus were investigated chemically. While A. candidus, isolated from
the marine sediment furnished p-terphenyl derivatives, the strain isolated from the gut of sea urchin
produced a different group of metabolites, i.e., spiculisporic derivatives. This fact has prompted us
to investigate the secondary metabolites from a marine-sponge associated strain of A. candidus to
verify if the marine host can influence the type of secondary metabolites produced by this fungus.
Our results were very interesting since we isolated, besides the commonly found fungal metabolites
such as palmitic acid, ergosterol-5,8-endoperoxide, the anthraquinones chrysophanic acid and emodin,
a diketopiperazine derivative, and bis-indolyl derivatives that are the chemical signature of this fungus,
one previously reported hydroxypyrrolidine alkaloid preussin (5a) and a new congener, preussin
C (5b). Although preussin (5a) was isolated from A. ochraceus and other fungi (Preussia sp. and
Simplicillium lanosoniveum), this is the first report of the isolation of hydroxypyrrolidine alkaloids
from A. candidus. From the biological perspective, it is interesting to note that although most of
the tested secondary metabolites exhibited a cytotoxic effect against eight human cancer cell lines,
their activity varied depending on the cell lines. The most notable aspect was that the presence of
the N-methyl group on the pyrrolidine ring in preussin (5a) was always crucial in both antibacterial
and cytotoxic activities. This was demonstrated by the effectiveness of preussin (5a) to decrease cell
viability when compared to the N-demethyl analogue, preussin C (5b). For the antibacterial activity
assay, it is important to point out that, among the compounds tested, only preussin (5a) stood out since
it displayed a relevant inhibitory effect against Gram-positive bacteria as well as methicillin-resistant
S. aureus (MRSA) and vancomycin-resistant enterococci (VRE) strains. Moreover, preussin (5a) was
not only able to interfere with biofilm formation in S. aureus ATCC 29213 and E. faecalis ATCC 29212
at concentrations equal to or above the MIC but also showed synergistic effect with vancomycin and
oxacillin against VRE and MRSA isolates and a strong synergistic effect with colistin when tested
against E. coli 1410/1. Therefore, our study reveals that preussin (5a) can represent a new model for
the development of a new class of antibiotic and anticancer agents.
Supplementary Materials: The following are available online at http://www.mdpi.com/1660-3397/16/4/119/s1,
Figure S1: Structures of palmitic acid, clionasterol and ergosterol-5,8-endoperoxide, isolated from the marine
sponge-associated fungus Aspergillus candidus KUFA0062, Figures S2–S35: 1D and 2D NMR spectra of isolated
compounds, Table S1: 1H NMR data of 2a–d (DMSO, 300.13 MHz), Table S2: 13C NMR data of 2a–d (DMSO,
75.3 MHz), Table S3: Comparison of 1H and 13C NMR data of 3 (DMSO, 300.13 and 75.4 MHz) and
2”-oxoasterriquinol D methyl ether (CDCl3, 300 MHz), Table S4: 1H and 13C NMR data of 4 (kumbicin D)
(300.13 MHz and 75.4 MHz).
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